Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments

CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035

Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research